4.6 Article

1-Year Survival After TAVR of Patients With Low-Flow, Low-Gradient and High-Gradient Aortic Valve Stenosis in Matched Study Populations

期刊

JACC-CARDIOVASCULAR INTERVENTIONS
卷 12, 期 8, 页码 752-763

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2019.01.233

关键词

low-flow; low-gradient aortic stenosis; propensity score matching; transcatheter aortic valve replacement; 1-year survival

资金

  1. Kerckhoff Heart Research Institute
  2. Justus Liebig University

向作者/读者索取更多资源

OBJECTIVES This study sought to examine whether the prognosis of patients with severe aortic stenosis (AS) having high versus low transvalvular mean pressure gradients (MPGs) is intrinsically different after transcatheter aortic valve replacement (TAVR), even after strict matching of baseline parameters. BACKGROUND Patients with low MPG are characterized by higher cardiovascular risk and more comorbidities than other AS patients are. METHODS In this retrospective, single-center study involving 2,282 patients, 3 groups were derived according to the following criteria: 1) high-gradient AS (HG-AS) (MPG >= 40 mm Hg); 2) low-flow, low-gradient AS (LFLG-AS) (MPG <40 mm Hg, ejection fraction [EF] <= 40%, stroke volume index <= 35 ml/m(2)); 3) paradoxical LFLG-AS (pLFLG-AS) (similar to LFLG-AS but with EF >= 50%). Propensity score matching that included EF was used to compare 1-year survival. RESULTS A total of 136 patients with HG-AS or LFLG-AS were identified. Kaplan-Meier survival curves were significantly different (p = 0.039), with death occurring in 11 versus 21 patients (hazard ratio: 2.12; 95% confidence interval: 1.02 to 4.39; p = 0.044), respectively. A total of 226 patients with HG-AS or pLFLG-AS were identified and here the curves were identical (p = 0.468), with death occurring in 18 versus 21 patients (hazard ratio: 1.26; 95% confidence interval: 0.67 to 2.38; p = 0.469). CONCLUSIONS This is the first study comparing survival after TAVR of patients with high versus low MPG in matched study populations. Mortality in patients with LFLG-AS was twice that of HG-AS patients. However, it appears that patients with pLFLG-AS might benefit from TAVR to the same extent as patients with HG-AS. There must be still unmasked factors that influence mortality of patients with LFLG-AS. (C) 2019 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据